Nasdaq: LQDALiquidia Corporation

    Liquidia Q3 2026 Results: Net Loss $236 Million on Revenue of $225 Million

    • US stocks
    • Earnings
    • Health Care
    A gloved hand using a pipette over a rack of sample tubes in a laboratory
    Centers for Disease Control and Prevention (CDC)/ Holly Patrick, MS, MPH, via Wikimedia Commons (public domain). Illustrative image.

    Liquidia (Nasdaq: LQDA) reported GAAP revenue of $225.3 million and a GAAP net loss of $236.3 million for the third quarter of 2026, and it said on 10 Nov 2026 that the loss included a $389.7 million litigation settlement charge. The GAAP diluted loss was $2.64 per share. The company also reported adjusted EBITDA of $140.5 million, a company-defined measure.

    Key highlights

    • Revenue (GAAP): $225.3 million, up 314.6% YoY
    • Net loss (GAAP): $236.3 million, including a $389.7 million litigation settlement charge
    • Diluted EPS (GAAP): -$2.64, against -$0.04 a year earlier
    • Adjusted EBITDA (company-defined): $140.5 million
    • Cash and cash equivalents: $396.1 million before settlement payments

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoY
    Revenue225.354.3+314.6%
    -263.51.8n/a
    -236.3-3.5-6589.2%
    Diluted EPS ($)-2.64-0.04-6500.0%

    Figures are in $ million except EPS; YoY compares with Q3 2025. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are the release's own comparatives, not cross-checked against SEC XBRL data. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table shows GAAP revenue of $225.3 million against $54.3 million a year earlier, an increase of 314.6%. The company's operating result moved from income of $1.8 million to a loss of $263.5 million. The net loss was $236.3 million against $3.5 million a year earlier. The year-ago column uses the release's own comparatives, the only source for those figures in this article.

    Adjusted EBITDA excludes the settlement charge

    Adjusted EBITDA is a non-GAAP measure that the company defines as net income before interest, income taxes, depreciation and amortization, and certain items. In this quarter the company's reconciliation also excludes the $389.7 million litigation settlement and $13.7 million of stock-based compensation. The company said adjusted EBITDA rose for a fifth consecutive quarter to $140.5 million.

    Settlement with United Therapeutics

    On 13 Oct 2026 Liquidia entered into a global settlement agreement with United Therapeutics that resolved all six pending lawsuits between the companies. The settlement followed a 30 Sep 2026 ruling by the U.S. District Court for the District of Delaware on certain patent claims related to inhaled treprostinil. The company said it agreed not to appeal that ruling, has submitted a filing to remove the PH-ILD indication from the YUTREPIA label, and has stopped promoting YUTREPIA for PH-ILD.

    Liquidia agreed to pay a net $380.7 million in installments in 2026 and 2027. The company said it expects to fund these payments from current cash and ongoing YUTREPIA sales. Cash and cash equivalents were $396.1 million at 30 Sep 2026, before the settlement payments.

    Product sales rose to $222.7 million

    Product sales, net, were $222.7 million against $51.7 million a year earlier. The company said the $171.0 million increase came from higher volume of YUTREPIA sales. The company also said total patient shipments in October 2026 reached their highest monthly level since launch.

    Research and development expenses were $25.3 million, up $16.0 million. The company said $11.1 million of that increase was for its L606 program. Selling, general and administrative expenses were $59.0 million. The Promotion Agreement with Sandoz, Inc. was terminated in October 2026, and the company said it will no longer generate service revenue.

    Inference

    The weighted average share count was 89,521,467, against 86,333,772 a year earlier. The release does not describe any share buybacks or dividends for the quarter.

    The release does not give full-year guidance, quarterly operating cash flow, or how much of the $380.7 million settlement had been paid by 30 Sep 2026.

    The settlement installments run through 2027, and the company anticipates starting the SPRINT study in 4Q2026.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts